Clinical Trial: Pegylated Liposomal Doxorubicin (PLD) Versus Active Surveillance for Advanced Soft Tissue Sarcoma Patients Who Had Controlled Disease After Standard Anthracycline-based Treatment (MELODY)

U.S., May 22 -- ClinicalTrials.gov registry received information related to the study (NCT06981637) titled 'Pegylated Liposomal Doxorubicin (PLD) Versus Active Surveillance for Advanced Soft Tissue Sarcoma Patients Who Had Controlled Disease After Standard Anthracycline-based Treatment (MELODY)' on May 05.

Brief Summary: Maintenance Pegylated Liposomal Doxorubicin (PLD) Versus Active Surveillance for Advanced Soft Tissue Sarcoma Patients Who Had Controlled Disease After Standard Anthracycline-based Treatment (MELODY)

Study Start Date: July 01

Study Type: INTERVENTIONAL

Condition: Advanced Soft Tissue Sarcoma

Intervention: DRUG: Pegylated liposomal doxorubicin

pegylated liposomal doxorubicin 40mg / m2 every 4 weeks for a maximum of 1...